Clinical Trial Update: Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) [Phase 2]

View source ↗

Summary

ADAPT-E is a Phase 2 clinical trial evaluating adjuvant ctDNA–guided, personalized treatment for early-stage non-small cell lung cancer and it is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Stanford University | Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I | Phase 2 | Status: RECRUITING